Supernus Pharmaceuticals, Inc.

This study tested the drug Qelbree (viloxazine) in 161 adults with ADHD who also had mood symptoms. Participants took the medication for several weeks, and researchers tracked changes in ADHD symptoms using a standard rating scale. The goal was to see if Qelbree is both safe and …

This study tested a drug called SAGE-547 in 132 people with super-refractory status epilepticus, a dangerous condition where seizures don't stop with standard treatments. The drug was given as a continuous IV infusion to see if it could help patients come off strong sedatives and…

This early-stage trial tested the safety and tolerability of an experimental drug called SAGE-718 in 6 healthy adults and a small group of people with Huntington's disease. Researchers looked for side effects and measured how the drug moves through the body. The goal was to see i…

This study tested an experimental drug called SAGE-718 in 26 people with mild cognitive impairment or mild dementia due to Alzheimer's disease. The main goal was to see if the drug is safe and tolerable, and to check for any effects on thinking and mood. Participants took SAGE-71…

This study tested a drug called SAGE-547 in 25 people with super-refractory status epilepticus, a condition where seizures continue despite standard treatments. The goal was to see if the drug is safe and tolerable. Participants received the drug by IV infusion, and researchers m…

This study tested four different doses of SPN-810 (molindone) in 78 children aged 6 to 12 with ADHD and serious conduct problems. The main goal was to see if the drug is safe and tolerable. Researchers measured behavior changes using a special rating scale. The trial is complete,…

This study tested an experimental drug called SAGE-547 (brexanolone) given as a 60-hour intravenous infusion to 138 women with severe or moderate postpartum depression. The goal was to see if it could quickly reduce depressive symptoms compared to a placebo. Results showed that t…

This study tested the safety of a drug called brexanolone in 28 teenage mothers with postpartum depression. The drug was given as an IV infusion. Researchers monitored side effects and how the drug moved through the body. The goal was to see if it could be a safe treatment option…

This study tested a drug called SAGE-547, given as an IV infusion over 60 hours, to see if it could reduce symptoms of postpartum depression in women. 108 women with moderate to severe depression after childbirth took part. The goal was to measure changes in depression scores com…

This study tested a drug called SAGE-718 in 174 people with mild cognitive impairment or mild dementia due to Alzheimer's disease. The goal was to see if the drug could improve cognitive performance, like processing speed and everyday task ability. Participants took either SAGE-7…

This study tested an experimental drug called SAGE-547, given as an IV infusion, in 21 adult women with severe postpartum depression. The goal was to see if it could quickly reduce depression symptoms compared to a placebo. The trial was randomized and double-blind, meaning neith…

This study tested whether the drug ZULRESSO (brexanolone) can be safely given to women with postpartum depression in their own homes instead of a hospital. Fifty-two women took part. The main goal was to see if any side effects caused the infusion to be stopped or interrupted. Th…

This early study tested an experimental drug called SAGE-547 in 4 women with severe postpartum depression. The main goal was to check safety and how the drug works in the body, not to prove it treats depression. Because it was very small and had no comparison group, the results a…

This study tested an experimental drug called SAGE-718 to see if it could improve cognitive function (like attention and processing speed) in people with Huntington's disease. 189 participants took either the drug or a placebo daily for a period of time. The main goal was to meas…

This small study tested a single 6-hour intravenous infusion of brexanolone in 10 adults with tinnitus. The main goal was to check safety and tolerability, while also measuring changes in tinnitus loudness. Results are limited due to the small size and lack of a placebo group.

This study tested whether SAGE-718, an experimental oral drug, can improve cognitive function in people with early Huntington's disease. 69 participants took either the drug or a placebo for 28 days. The main goal was to measure changes in thinking skills using a battery of cogni…

This small study tested an experimental drug called SAGE-718 in 18 people with Parkinson's disease who also had mild thinking and memory problems. The main goal was to see if the drug was safe and tolerable. Researchers also looked at whether it might help with thinking, mood, an…

This study tested a drug called SAGE-718 in 86 people with Parkinson's disease who have mild memory or thinking problems. Participants took either the drug or a placebo pill for a set time. The main goal was to see if SAGE-718 could improve processing speed, measured by a symbol-…

This early-phase trial gave 22 healthy adults a single dose of SAGE-718 or a placebo, followed by a ketamine infusion, to see how the drug affects brain electrical activity. The study was completed and focused on safety and how the body processes the drug. Since it involved healt…

This Phase 1 study tested an experimental drug called SAGE-718 in 19 healthy volunteers. Participants received either SAGE-718 or a placebo, along with ketamine, to see how the drug affects brain chemicals like glutamate. The goal was to check safety and measure brain activity us…

This early-stage study tested a drug called SAGE-718 in 40 healthy adults. Researchers used a ketamine challenge to see how the drug affects brain electrical activity and safety. The goal was to gather basic information, not to treat any illness. This is a first step toward under…

This early-stage study tested a drug called SAGE-904 in 22 healthy volunteers to see how it changes brain activity after a ketamine challenge. Researchers measured brain waves using EEG to check if SAGE-904 alters responses to sounds. The goal was to understand how the drug works…